A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: Patients are eligible for inclusion in the study only if they meet all of the following criteria: 1. Patient has received at least 1 dose of an RPx product and has completed or discontinued participation in the parent study. 2. Patient or patient's legal guardian has provided signed informed consent (or assent) as , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion Criteria: Patients are excluded from the study if the following criterion applies: 1\. Cannot comply with the requirements of the study.
About the study
This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose of an RPx product under the interventional parent study. Patients will be rolled over into this LTFU study after completion of the Replimune-sponsored parent study (ie, either completion of the LTFU in the parent study or withdrawal from the parent study). All patients in ongoing RPx studies will be asked to participate in this LTFU study so that the Sponsor can evaluate potential delayed risks.
What is being tested
- Observational study with no interventions (other)
Sponsor: Replimune, Inc. · Participants: 50 · Started: Dec 12, 2025
Contact the study team
- Clinical Trials at Replimune · Phone: 1-781-222-9570
Official record on ClinicalTrials.gov — NCT06887348
Locations in the U.S.
| California | UC San Diego Moores Cancer Center, La Jolla |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.